Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
AUPH Stock Chart & Stats
$12.12
$0.10(1.19%)
At close: 4:00 PM EST
$12.12
$0.10(1.19%)
Day’s Range― - ―
52-Week Range$6.55 - $13.54
Previous CloseN/A
Volume460.34K
Average Volume (3M)1.55M
Market Cap
$1.60B
Enterprise ValueN/A
Total Cash (Recent Filing)$315.13M
Total Debt (Recent Filing)$81.83M
Price to Earnings (P/E)28.3
Beta0.69
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding131,629,550
10 Day Avg. Volume1,080,974
30 Day Avg. Volume1,553,148
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$12.20Price Target Upside0.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAUR200 phase 1 trial showed the drug was well tolerated at all dose levels with no treatment-related serious adverse events.
Financial PerformanceAurinia Pharmaceuticals reported strong 2Q25 financial results with total revenue exceeding consensus estimates, indicating robust company performance.
Sales GrowthThe company incrementally increased FY25 net product sales guidance to $250-260M.
Bears Say
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $6.55 and its highest was $13.54 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.60B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 124 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 131,629,550 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.20 (0.66% Upside)
$12.20 (0.66% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $13.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.67%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
-4.00%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for kidney diseases, particularly lupus nephritis. The company is primarily engaged in the research and development of its lead product, LUPKYNIS (voclosporin), which is designed to improve renal response in patients with this autoimmune condition. Based in Victoria, British Columbia, Aurinia operates in the biopharmaceutical sector, leveraging its expertise in immunology and nephrology to address significant unmet medical needs.
AUPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Aurinia Pharmaceuticals reported strong financial performance with significant revenue and net product sales growth, improved cash flow, increased guidance, and successful clinical trial results. However, there were decreases in cash, cash equivalents, and investments due to share repurchases.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$12.20
▲(0.66% Upside)
Technical Analysis
Ownership Overview
11.53% Insiders
4.91% Mutual Funds
0.14% Other Institutional Investors
76.66% Public Companies and Individual Investors